DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lanthanum carbonate
Lanthanum carbonate
How to Take Your Phosphate Binders
Effect of Lanthanum Carbonate and Calcium Acetate in the Treatment of Hyperphosphatemia in Patients of Chronic Kidney Disease P
Fosrenol-Pm-En.Pdf
Laaketilasto07 2.Pdf
Chronic Kidney Disease (CKD) in Dogs & Cats
Sucroferric Oxyhydroxide 500Mg Chewable Tablets (Velphoro®) SMC No
Effects of Lanthanum Carbonate on the Absorption and Oral Bioavailability of Ciprofloxacin
C:\Data\NDA 21468 Lanthanum Carbonate
205739Orig1s000
FOSRENOL (Lanthanum Carbonate)
Table 1 2009 Community Prescription Numbers
Australian Public Assessment Report for Sodium Zirconium Cyclosilicate Hydrate
Fosrenolsol.Pdf
Therapeutic Class Overview Electrolyte Depleters
Clinical Protocol ZS-004
Attachment: Extract from Clinical Evaluation Report Sodium
And Sevelamer Carbonate (Renvela®) Application with Prescription
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
Top View
Fosrenol Chewable Tablet
Therapeutic Class Overview Electrolyte Depleters
Product Monograph Fosrenol®*
Phosphate Binders (Non-Calcium, Non-Aluminum) Lanthanum Carbonate, Sevelamer Carbonate, Ferric Citrate, Sucroferric Oxyhydroxide
Phosphate Binders
Clinical Review Report for Sodium Zirconium Cyclosilicate (Lokelma) 2
Lanthanum Carbonate Report (Adopted by the CCG Until Review and Further Notice)
Oral Phosphate Binders in Patients with Kidney Failure
Suomen Lääketilasto 2015
Lanthanum Carbonate
Calcium Acetate 435Mg/Magnesium Carbonate 235Mg Tablet (Osvaren®) SMC No
Cost Effectiveness of Lanthanum Carbonate in Chronic Kidney
Study Protocol
CTRI Trial Data
Medication Coverage Policy
A Comparison of Clinically Useful Phosphorus Binders for Patients with Chronic Kidney Failure
Fosrenol, Chewable Tablet
Guidelines for ATC Classification and DDD Assignment 2021
A13-15 Colestilan – Benefit Assessment According 1 to § 35A Social Code Book V
Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Guidelines for ATC Classification and DDD Assignment 2013
Baltic Statistics on Medicines 2010–2012 2 | Sales Statistics 2010–2012 Sales Statistics 2010–2012 |
The Treatment Concepts of Hyperphosphatemia in CKD And
Phosphate Binders in Patients with Chronic Kidney Disease
207078Orig1s000
Phosphate Binders Review – September 2020 Page 2 | Proprietary Information
Effect of Patiromer on Serum Potassium Level In
Lokelma: EPAR – Public Assessment Report
Effect of Calcium Acetate/Magnesium Carbonate in the Treatment of Hyperphosphataemia in Dialysis Patients in Real Clinical Practice
Draft Guidance on Sodium Zirconium Cyclosilicate August 2021
Public Assessment Report